CD8A and neoplasm: In summary, the loss of heterozygosity of HLA and the mutation of B2M dampen the processing and presentation of antigens, resulting in the inability of CD8+ T cells to recognize tumor antigens and specifically kill tumor cells, which represents an important mechanism of primary or acquired resistance to ICB therapy.